Meeting
2016 Palliative and Supportive Care in Oncology Symposium
Efficacy of anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m2): Post-hoc analysis of two phase III studies.
Authors
David Christopher Currow
Cancer Institute NSW, Adelaide, Australia
David Christopher Currow, Jennifer S. Temel, Amy Pickar Abernethy, Ruben Giorgino, John Friend, Kenneth Fearon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Biologic Basis of Symptoms and Treatment Toxicities,Psycho-oncology,End-of-Life Care,Survivorship,Management/Prevention of Symptoms and Treatment Toxicities,Psychosocial and Spiritual Care,Communication in Advanced Cancer
Sub Track
Symptom management
Clinical Trial Registration Number
NCT01387282; NCT01387269
Citation
J Clin Oncol 34, 2016 (suppl 26S; abstr 203)
DOI
10.1200/jco.2016.34.26_suppl.203
Abstract #
203
Poster Bd #
G5
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m2): A pooled efficacy data analysis of two phase 3 studies.
First Author: David Christopher Currow
Poster
2022 ASCO Annual Meeting
Body weight (BW) response timing to anamorelin (ANAM) in advanced non–small cell lung cancer (NSCLC)–associated cachexia.
First Author: Richard J.E. Skipworth
Poster
2015 Palliative and Supportive Care in Oncology Symposium
Anamorelin in patients with advanced non-small cell lung cancer and cachexia: Results from the phase III studies ROMANA 1 and 2.
First Author: Jennifer S. Temel
Poster
2014 Palliative and Supportive Care in Oncology Symposium
Subgroup analysis of ECOG2 patients from ROMANA 2: A phase III study of anamorelin in NSCLC patients with cachexia.
First Author: Amy Pickar Abernethy